Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GOVX

Geovax Labs Inc

Apr 15 • 11:45AM ET

1.27

-0.07 -5.22 %

Healthcare • Biotechnology • USA • NASD

Peers: INO NVAX VXRT ALT BNTX CVAC MOD HEPA ITRM HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-47.34	Insider Own	0.20%	Shs Outstand	2.22M	Perf Week	7.63%
Market Cap	2.82M	Forward P/E	-	EPS next Y	-13.00	Insider Trans	0.00%	Shs Float	2.22M	Perf Month	-25.73%
Enterprise Value	-2.19M	PEG	-	EPS next Q	-6.26	Inst Own	5.32%	Short Float	11.40%	Perf Quarter	-63.51%
Income	-25.31M	P/S	0.84	EPS this Y	21.07%	Inst Trans	6.64%	Short Ratio	2.10	Perf Half Y	-90.86%
Sales	3.35M	P/B	0.31	EPS next Y	49.51%	ROA	-283.68%	Short Interest	0.25M	Perf YTD	-70.29%
Book/sh	4.13	P/C	0.56	EPS next 5Y	27.86%	ROE	-377.44%	52W High	34.75 -96.35%	Perf Year	-94.03%
Cash/sh	2.25	P/FCF	-	EPS past 3/5Y	52.75% 78.99%	ROIC	-515.77%	52W Low	1.14 11.72%	Perf 3Y	-99.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	117.28% 27.45%	Gross Margin	163.97%	Volatility	9.57% 9.28%	Perf 5Y	-99.93%
Dividend TTM	-	EV/Sales	-0.65	EPS Y/Y TTM	79.51%	Oper. Margin	-761.63%	ATR (14)	0.14	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	3.57	Sales Y/Y TTM	8.52%	Profit Margin	-754.69%	RSI (14)	36.77	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.57	EPS Q/Q	65.70%	SMA20	-6.17%	Beta	3.66	Target Price	200.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	-25.21%	Rel Volume	0.76	Prev Close	1.34
Employees	-	LT Debt/Eq	0.00	Earnings	Mar 26	SMA200	-87.33%	Avg Volume	120.71K	Price	1.27
IPO	May 12, 1997	Option/Short	No / Yes	EPS/Sales Surpr.	-1.47% -	Trades		Volume	34,726	Change	-5.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-19-26	Downgrade	D. Boral Capital	Buy → Hold
Apr-15-25	Reiterated	D. Boral Capital	Buy	$18 → $14
Apr-15-25	Reiterated	Alliance Global Partners	Buy	$15 → $8.50
Nov-11-24	Initiated	Alliance Global Partners	Buy	$15
Jul-16-24	Initiated	ROTH MKM	Buy	$20
Nov-19-20	Initiated	Maxim Group	Buy	$8

Apr-14-26 09:00AM	GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market (NewMediaWire)
Apr-02-26 09:00AM	GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026 (NewMediaWire) -5.67%
Mar-31-26 02:33PM	GeoVax Announces a Warrant Inducement Transaction (NewMediaWire)
Mar-25-26 09:00AM	GeoVax Provides Update on GEO-MVA Program (NewMediaWire)
Mar-12-26 09:00AM	GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients (NewMediaWire)
09:00AM	Loading…
Mar-11-26 09:00AM	GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine (NewMediaWire)
Feb-24-26 09:00AM	GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors (NewMediaWire)
Feb-19-26 09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly) +12.23%
Feb-18-26 09:00AM	GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology (NewMediaWire) -12.03%
Feb-17-26 09:00AM	GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over (NewMediaWire) -5.95%
Feb-13-26 08:00AM	GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (NewMediaWire) -27.27%
Jan-20-26 09:00AM	GeoVax Highlights 2026 as a Pivotal Year for Progress (NewMediaWire) -6.69%
Jan-08-26 09:00AM	GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement (NewMediaWire) -9.23%
Jan-06-26 09:00AM	GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week (NewMediaWire) +14.47%
Dec-19-25 09:24AM	GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering (NewMediaWire) -33.69%
01:00PM	Loading…
Dec-18-25 01:00PM	GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine (NewMediaWire)
09:00AM	GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA (NewMediaWire)
Dec-17-25 09:00AM	GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026 (NewMediaWire) -12.74%
Dec-16-25 09:00AM	GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design (NewMediaWire) -13.99%
Dec-15-25 09:00AM	GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients (NewMediaWire) -11.13%
Dec-11-25 09:00AM	GeoVax Addresses Identification of New Mpox Variant (NewMediaWire)
Dec-10-25 09:00AM	GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board (NewMediaWire)
Dec-09-25 09:00AM	GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy (NewMediaWire)
Dec-08-25 09:00AM	GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer (NewMediaWire) +9.33%
Nov-24-25 09:00AM	GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference (NewMediaWire)
Nov-14-25 06:00PM	Geovax Labs Inc (GOVX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -9.11%
Nov-13-25 04:00PM	GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update (NewMediaWire) -5.80%
Nov-10-25 09:00AM	GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination (NewMediaWire)
Nov-04-25 09:00AM	GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025 (NewMediaWire) -5.18%
Nov-03-25 09:00AM	GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement (NewMediaWire)
01:00PM	Loading…
Oct-30-25 01:00PM	BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now (NewMediaWire)
Oct-29-25 09:00AM	GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1 (NewMediaWire) -7.81%
Oct-28-25 09:00AM	GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients (NewMediaWire)
Oct-20-25 10:30AM	GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases (NewMediaWire) +8.16%
Oct-16-25 09:00AM	GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025 (NewMediaWire) -5.80%
Oct-13-25 09:00AM	GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions (NewMediaWire)
Oct-09-25 09:00AM	GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025 (NewMediaWire)
Oct-07-25 09:00AM	GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference (NewMediaWire)
Oct-01-25 09:00AM	GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit (NewMediaWire) +13.93%
Sep-30-25 09:07AM	GeoVax Labs Announces $2.5 Million Registered Direct Offering (NewMediaWire) -24.79%
Sep-29-25 09:00AM	GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security (NewMediaWire)
Sep-24-25 09:00AM	GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications (NewMediaWire)
Sep-22-25 09:00AM	GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations (NewMediaWire)
Sep-18-25 09:00AM	GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference (NewMediaWire)
Sep-15-25 09:00AM	GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference (NewMediaWire)
Sep-12-25 09:00AM	GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference (NewMediaWire)
Sep-08-25 09:00AM	GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences (NewMediaWire)
Sep-03-25 09:00AM	GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference (NewMediaWire)
Aug-20-25 12:00PM	GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.33%
09:00AM	GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs (NewMediaWire)
Aug-18-25 09:00AM	GeoVax to Present at the Emerging Growth Conference on August 20, 2025 (NewMediaWire)
Aug-07-25 09:00AM	GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine (NewMediaWire)
Jul-30-25 09:00AM	GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains (NewMediaWire)
Jul-29-25 09:00AM	GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation (NewMediaWire)
03:04AM	Geovax Labs Inc (GOVX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Jul-28-25 04:00PM	GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update (NewMediaWire) -6.33%
09:00AM	GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology (NewMediaWire)
Jul-24-25 09:00AM	GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results (NewMediaWire)
Jul-22-25 09:00AM	GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025 (NewMediaWire)
Jul-21-25 09:00AM	GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine (NewMediaWire) +7.19%
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +6.43%
09:00AM	GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand (NewMediaWire)
Jul-15-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream (GlobeNewswire)
Jul-14-25 09:00AM	GeoVax to Present at the Emerging Growth Conference on July 16, 2025 (NewMediaWire)
Jul-03-25 09:00AM	GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat (NewMediaWire)
Jul-02-25 09:30AM	GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives (NewMediaWire)
Jul-01-25 08:30AM	GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering (NewMediaWire) -43.98%
Jun-25-25 08:00AM	GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection (NewMediaWire)
Jun-24-25 09:00AM	GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy (NewMediaWire)
Jun-17-25 09:00AM	GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting (NewMediaWire) -31.82%
Jun-16-25 09:00AM	GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA (NewMediaWire) +28.16%
Jun-12-25 09:00AM	GeoVax to Participate in BIO International Convention 2025 (NewMediaWire)
Jun-11-25 09:00AM	GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency (NewMediaWire) -6.56%
Jun-10-25 09:00AM	GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients (NewMediaWire)
Jun-09-25 09:00AM	GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia (NewMediaWire) +5.36%
Jun-04-25 09:00AM	GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology (NewMediaWire) +6.67%
May-29-25 09:00AM	GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing (NewMediaWire)
May-27-25 11:00AM	GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance (NewMediaWire) +6.93%
May-21-25 09:00AM	GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation (NewMediaWire) -5.78%
May-20-25 09:00AM	GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations (NewMediaWire)
May-08-25 09:00AM	GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 (NewMediaWire)
May-07-25 09:00AM	GeoVax Expands Gedeptin(R) Patent Portfolio (NewMediaWire)
May-06-25 03:00PM	GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production (NewMediaWire) -7.86%
May-01-25 08:58PM	GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:00PM	GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update (NewMediaWire)
Apr-29-25 12:00PM	GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting (NewMediaWire)
Apr-24-25 04:02PM	GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater (NewMediaWire) +17.92%
12:00PM	GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress (NewMediaWire)
Apr-23-25 09:00AM	GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 (NewMediaWire)
Apr-22-25 09:00AM	GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations (NewMediaWire) +7.60%
Apr-16-25 04:00PM	GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates (NewMediaWire) +6.09% -8.08%
10:15AM	GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital (TipRanks)
09:00AM	GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum (NewMediaWire)
07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 01:25PM	GeoVax to Present at the Emerging Growth Conference on April 16, 2025 (NewMediaWire) -20.50%
09:00AM	GeoVax to Present Clinical Data at Upcoming April Industry Events (NewMediaWire)
07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire)
Apr-09-25 09:00AM	GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent (NewMediaWire) +7.21%
Mar-27-25 08:53PM	GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript (Seeking Alpha) -7.30% -12.60%
04:00PM	GeoVax Reports 2024 Year-End Financial Results and Provides Business Update (NewMediaWire)

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKee Kelly T. Jr.	Chief Medical Officer	Aug 07 '25	Buy	0.67	1,107	742	3,494	Aug 08 03:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOVX

Geovax Labs Inc

Upgrade your Finviz experience